Bhattacharjee A K, Cross A S
Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC, USA.
Infect Dis Clin North Am. 1999 Jun;13(2):355-69, vii. doi: 10.1016/s0891-5520(05)70079-9.
Antibodies to various core glycolipid antigens have been shown to correlate with survival from Gram-negative sepsis. Recent preclinical data also support efficacy of the anti-core glycolipid antibodies in the treatment of sepsis. Failure of some of the previous clinical trials with anti-core glycolipid antibody was probably due to inadequate levels of antibody in those preparations. Future clinical trials must ensure that sufficient amounts of anti-core glycolipid antibodies are present in the circulation of patients with sepsis.
已证实，针对各种核心糖脂抗原的抗体与革兰氏阴性菌败血症的存活率相关。近期的临床前数据也支持抗核心糖脂抗体在败血症治疗中的疗效。先前一些抗核心糖脂抗体临床试验的失败可能是由于这些制剂中抗体水平不足。未来的临床试验必须确保败血症患者的循环系统中有足够量的抗核心糖脂抗体。
